Lan bɔt Herceptin (Trastuzumab) tritmɛnt fɔ HER2-positiv brɔst kansa

We dɛn no se yu ɔ pɔsin na yu famili gɛt bɔdi kansa, i nɔ kin izi fɔ tɔk bɔt di fred ɛn wɔri we yu de fil. Na tɛm we pɔsin kin rili fil bad. Bɔt, di tin we impɔtant pas ɔl na dat wit di advans mɛdikal sayɛns we wi gɛt naw, wi kin gɛt op. Yu dɔktɔ go tink bɔt bɔku tin dɛn lɛk di kayn kansa we yu gɛt, yu ej, ɛn if yu gɛt ɔda sik, fɔ pik di bɛst tritmɛnt fɔ yu. Bɔku tɛm, dɛn kin trit di bɔdi kansa wit ɔpreshɔn, kemotɛrapi, ɛn raytin.

Tide wi de tɔk bɔt wan tritmɛnt we difrɛn smɔl, we spɛshal. Dɛn kɔl dis " targeted therapy." Herceptin na wan pan dɛn kayn mɛrɛsin dɛn de. Di nem we i gɛt fɔ mɛn pipul dɛn na Trastuzumab . Yu go dɔn yɛri se dɛn kɔl am ɔda nem dɛn lɛk Kanjinti, Herzuma, Ogivri. dεn kכl dεn tin ya ``biosimilars.'' Fכ simpul wan, dεn na bayolojikal kכpi dεm fכ di sem dכg we Herceptin.

Wetin na Targeted Therapy ɛn Herceptin?

Tink bɔt am, di kemotɛrapi mɛrɛsin dɛn we dɛn kin gi ɔltɛm nɔto jɔs di kansa sɛl dɛn nɔmɔ, bɔt i kin afɛkt di wɛlbɔdi sɛl dɛn bak we kin sheb kwik kwik wan. Bɔt di tritmɛnt dɛn we dɛn kin yuz fɔ mɛn pipul dɛn we dɛn kin tɔk to nɔ tan lɛk dat. Dɛn kin wok bay we dɛn de tɔch sɔm patikyula tin dɛn we dɛn want fɔ du. Dɛn mɛrɛsin ya kin kɔntrol sɔm patikyula prɔtin dɛn we kin ɛp di kansa sɛl dɛn fɔ gro ɛn fɔ skata. Na dat mek dɛn nɔ de wok fɔ ɔl kansa. di protin we di dכg de tכk bכku bכku wan insay dεn kεnsar sεl dεm de.

Di drɔg we dɛn kɔl Herceptin de tɔch wan prɔtin we dɛn kɔl HER2 . (di ful nem fכ dis na `human epidermal growth factor rεsεpכta 2`). so, if dis HER2 protin de prodyuz pasmak insay di kεnsar sεl dεm, wi kin kכl da kayn brεst kεnsar de `HER2-positiv` brεst kεnsar. dεn de gi hεrseptin tritmεnt nכmכ to dεn `HER2-positiv` tכp brεst kεnsar.

Aw dis Herceptin drɔg de wok insay di bɔdi?

Fɔ ɔndastand dis, lɛ wi fɔs luk wetin na HER2. HER2 na rεsεpכta we de na di sεl dεm. Tink bɔt am lɛk smɔl ɛntena we de ɔp wan sɛl. Dɛn ɛntena dɛn ya na di wan dɛn we de gɛt signal frɔm ɔdasay na di sɛl ɛn akt pan dɛn. insay wan hεlty sεl, di HER2 rεsεpכta dεm de fכ kכntrכl di sεl dεm we de gro.

bכt sכmtin difrεnt de apin insay `HER2-positiv` kεnsar sεl dεm. dis sεl dεm gεt εkstra kכpi dεm fכ di jin dεm we de mek di HER2 protin. so, dεn sεl dεm ya de mek tu mכch pan di HER2 protin. I tan lɛk se tumɔs ɛntena dɛn de na di sɛl. afta dat, di kεnsar sεl dεm gεt tu mכch signal fכ "grכw, divayd," εn dεn de gro aut כf kכntrol, rili kwik.

Yu tink se Herceptin tritmɛnt fayn fɔ mi kansa?

Dis na kwɛstyɔn we rili impɔtant. if yu brεst kεnsar na `HER2-nεgεtiv`, we min se di kεnsar sεl dεm nכ gεt di εkstra HER2 protin, den Herceptin tritmεnt nכ go wok. כl di brεst kεnsar dεm na `HER2-nεgεtiv`. Na lɛk 20% na HER2-pɔzitiv. Yu dɔktɔ go tɛl yu ustɛm di kayn kansa yu gɛt tru tɛst.

Dɛn kin yuz hɛrɛseptin tritmɛnt na di fɔs stej dɛm fɔ brɛst kansa, ɛn bak na di advans stej dɛm usay di kansa dɔn skata (mɛtastatik).

• Fɔ di kansa we de bigin: If yu kansa gɛt HER2 ɛn na di fɔs stej, dɛn kin gi yu Herceptin fɔ mek di kansa nɔ kam bak afta dɛn dɔn du di ɔpreshɔn. Bɔku tɛm dɛn kin gi dis wit kemotɛrapi ɔ ɛndokrin tɛrapi. Dɛn kin gi dis tritmɛnt mɔ if di kansa big ɔ i dɔn spre to di limf no dɛm.

• Fɔ kansa we dɔn go bifo: If di kansa dɔn skata to fa fa pat dɛm na di bɔdi (metastatic), Herceptin kin ɛp fɔ stɔp ɔ slo fɔ gro. Sɔntɛnde, if di tumbu tu big fɔ mek dɛn pul am bay ɔpreshɔn, Hɛsɛptin ɛn ɔda tritmɛnt dɛn kin mek i smɔl bifo dɛn du di ɔpreshɔn.

Wetin yu fɔ ɛkspɛkt we yu de gɛt tritmɛnt?

dεn de gi hεseptin as infushכn (intravenכs - IV) insay wan vein. Dɛn kin gi am as salin sɔlvushɔn. Dɛn kin du dis bikɔs dɛn nid fɔ put di mɛrɛsin dairekt insay di blɔd. I kin tek bitwin 30 ɛn 90 minit fɔ dɔn.

Wan kayn dis de bak we dɛn kin gi as injɛkshɔn. Dɛn kɔl am `Herceptin Hylecta`. Stɔdi dɔn sho se dis kin wok jɔs lɛk aw di IV kin wok. Yu dɔktɔ go disayd us we fɔ du am bɛtɛ fɔ yu.

Aw lɔng ɛn aw ɔltɛm yu nid fɔ tek Herceptin de dipen pan di stej we yu kansa gɛt ɛn di ɔda mɛrɛsin dɛn we yu de tek. If di kansa dɔn go bifo (metastatic), yu kin nid fɔ kɔntinyu fɔ trit am as lɔng as di mɛrɛsin de wok ɛn no siriɔs sayd ɛfɛkt nɔ de.

I rili impɔtant: Yu dɔktɔ go chɛk yu at fɔ wok ɔltɛm bifo ɛn di tɛm we dɛn de tek di tritmɛnt we dɛn kɔl Herceptin, bikɔs dis mɛrɛsin kin afɛkt di at sɔntɛnde.

Apat frɔm dis, ɔda bad bad tin dɛn kin apin. So, bifo yu bigin fɔ trit yu, yu fɔ tek tɛm lan us sayn dɛn fɔ wach fɔ ɛn ustɛm fɔ tɛl yu dɔktɔ wantɛm wantɛm. Dɛn nɔ kin gi ɛrseptin tritmɛnt to uman dɛn we gɛt bɛlɛ ɔ we de tray fɔ gɛt bɛlɛ.

Aw dis tritmɛnt kin wok fayn?

Herceptin na wan drɔg we rivɔlɔshɔn di tritmɛnt fɔ HER2-positiv brɔst kansa afta dɛn dɔn gri fɔ am insay 1998.

• Fɔ kansa we dɔn go bifo: we dɛn gi am Hɛsɛptin in wan ɔ wit kemotɛrapi, i kin mek di kansa nɔ gro sloslo ɛn ɛp di wan dɛn we sik fɔ liv lɔng. Bɔt sɔntɛnde, di mɛrɛsin kin wok fɔ sɔm tɛm ɛn i kin stɔp fɔ wok.

• Fɔ kansa we de bigin: Na dis say dɛn kin si di big big sakrifays. Stɔdi dɔn sho se if yu ad Herceptin to kemotɛrapi afta yu du ɔpreshɔn, i kin ridyus di risk fɔ mek di kansa kam bak bay lɛk 50% . Dis min se mɔ uman dɛn we de tek Herceptin de liv lɔng we dɛn nɔ gɛt kansa.

Pan ɔl we dɛn kin gi tritmɛnt fɔs fɔ wan ɔ tu ia, stɔdi dɛn we dɛn jɔs dɔn du sho se fɔ bɔku pipul dɛn, if dɛn tek Herceptin fɔ lɛk 6 mɔnt so, i go du fɔ dɛn. Dis na gud nyus fɔ di wan dɛn we de wɔri bɔt di bad tin dɛn we kin apin to dɛn.